The effect of low-dose aspirin on the pregnancy rate in frozen-thawed embryo transfer cycles: A randomized clinical trial

Robab Davar, Soheila Pourmasumi, Pourmasumi S, Mohammadi B, Banafsheh Mohammadi, Maryam Mortazavi Lahijani, Lahijani MM
International journal of reproductive biomedicine · 2020 · vol. 18(9) , pp. 693–700 · doi:10.18502/ijrm.v13i9.7664 · PMID:33062915 · PMC7521165
RCT OA: gold CC-BY-NC-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-03 ⓘ

This randomized clinical trial found that low-dose aspirin administered during frozen-thawed embryo transfer cycles did not improve implantation or pregnancy rates compared to no treatment, although it reduced endometrial thickness.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text ⓘ

This randomized clinical trial evaluated whether low-dose aspirin improves pregnancy outcomes in women undergoing frozen-thawed embryo transfer cycles. The study included 128 patients assigned to either an aspirin group or a control group, measuring primary outcomes such as clinical pregnancy and implantation rates. Results indicated no statistically significant difference in pregnancy or implantation rates between the two groups, while the aspirin group exhibited significantly lower endometrial thickness. The authors concluded that routine aspirin administration does not benefit these cycles and aligns with existing reviews recommending against its use in assisted reproductive technology. Relevance to endometriosis: explicitly excluded from the study population via inclusion criteria requiring "no endometriosis," making it tangentially related as a condition ruled out during participant selection.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: The results of previous studies on the effect of low-dose aspirin in frozen-thawed embryo transfer (FET) cycles are limited and controversial. OBJECTIVE: To evaluate the effect of low-dose aspirin on the clinical pregnancy in the FET cycles. MATERIALS AND METHODS: This study was performed as a randomized clinical trial from May 2018 to February 2019; 128 women who were candidates for the FET were randomly assigned to two groups receiving either 80 mg oral aspirin (n = 64) or no treatment. The primary outcome was clinical pregnancy rate and secondary outcome measures were the implantation rate, miscarriage rate, and endometrial thickness. RESULTS: The endometrial thickness was lower in patients who received aspirin in comparison to the control group. There were statistically significant differences between the two groups (p = 0.018). Chemical and clinical pregnancy rates and abortion rate was similar in the two groups and there was no statistically significant difference. CONCLUSION: The administration of aspirin in FET cycles had no positive effect on the implantation and the chemical and clinical pregnancy rates, which is in accordance with current Cochrane review that does not recommend aspirin administration as a routine in assisted reproductive technology cycles.
Full text 12,003 characters · extracted from pmc-nxml · 2 sections · click to expand

Section

Our study concludes that the administration of aspirin in frozen-thaw cycles had no positive effect on the implantation, chemical, and clinical pregnancy rates, and is in accordance with the current Cochrane review that does not recommend aspirin administration as a routine in ART cycles.

Coi Statement

The authors have no financial or nonfinancial conflicts of interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T21:28:48.188428+00:00
unpaywall
last seen: 2026-05-21T05:10:58.409756+00:00
License: CC-BY-NC-4.0